luminal


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to luminal: veronal, Seconal, lumen

lu·mi·nal

(lū'mi-năl), [TA]
Relating to the lumen of a blood vessel or other tubular structure.
Synonym(s): luminalis [TA]

Luminal®

Phenobarbital, see there.

lu·mi·nal

(lū'mi-năl) [TA]
Relating to the lumen of a blood vessel or other tubular structure.
Synonym(s): luminalis.

luminal

Pertaining to a LUMEN.
References in periodicals archive ?
The results show that patients with Luminal A breast cancer had a relatively small but prolonged risk increase for metastatic cancer, and that tamoxifen treatment significantly reduced this risk for as long as 15 years after diagnosis.
They discovered that luminal cells from older animals formed prostate organoids just as effectively as cells from younger animals.
(47) These markers included GATA3, CK18, CK20, uroplakin II, cyclin D1, and ERBB2 for the luminal markers; CK5/6, CK14, and p63 for the basal markers; and p16, B-cell lymphoma 2 (BCL2), smooth muscle actin (SMA), myosin, calponin, and desmin for the p53-like subtype markers.
In our study, detection of ARIDIA tissue expression in the luminal group breast cancers which is especially associated with better prognosis supports the prognostic role of ARIDIA mutations in breast cancer.
Distribution of Stromal Density, MVD, TAM with Molecular Subtype of Carcinoma Breast Molecular Stromal MVD TAM Subtype Density Low High Low High Low High Luminal A 44 23 37 30 36 31 Luminal B 23 13 26 10 17 19 Her 2 12 1 4 9 7 6 enriched Basal like 10 8 12 6 7 11 No statistically significant association was found between stromal density (p=0.173), MVD (0.052) and TAM (p=0.052) with molecular subtype of carcinoma.
The researchers also discovered that the greater risk of death for patients with high intra-tumour heterogeneity also applied to patients with Luminal A breast cancer, a subtype of oestrogen-receptor-positive breast cancer that is considered to have a good prognosis.
Gene expression profiling has established that breast cancer comprises a group of biologically distinct diseases.[1],[2] According to St Gallen International Breast Cancer Conference (2011), breast cancer subtypes (BCS) are classified as luminal A; luminal B; luminal human epidermal growth factor receptor 2 (HER2); HER2; and triple negative (TN).[3],[4] Significant differences have been observed in response to treatment and survival outcome among these BCS.[5],[6],[7],[8] Therefore, accurate prognosis depends on multiple variables.
The rationale of this technique is that the blades of the balloon would easily create microfenestrations and reentry points at the intima that will eventually allow the intramural blood to exit and induce decompression of the medial space with successive resolution of the luminal stenosis (Figure 4).
Thus, the identification of the mechanisms underlying the acquisition of metastasis-enabling features and the generation of a permissive microenvironment for tumor growth and invasion can help identify luminal B BC patients at high risk of relapse and may represent the rationale for the development of novel therapeutic strategies.
In active disease (Figure 1(a)), there is a pronounced down-regulation of the SMAD4 protein expression in particular on the apical epithelial surface (luminal SMAD4) compared with controls (Figure 1(c)).